Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE The three RAS genes (HRAS, NRAS, and KRAS) comprise the most frequently mutated oncogene family in human cancer. 31815779

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Positive concordance rate for KRAS alterations was 57.1% vs. 27.4% (colorectal vs. noncolorectal cancer; p = 0.01), but site of biopsy (primary vs. metastatic) and VAF (%ctDNA) was not impactful. 31199507

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE We first performed siRNA screen of KRAS growth dependency of a small panel of human cancer lines, and identified a subset of KRAS mutant cancer cells that were highly dependent on KRAS signaling. 31316177

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling. 31605540

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE The three canonical genes (HRAS, NRAS, and KRAS) are archetypes of the superfamily of small GTPases and are the most common oncogenes in human cancer. 31386964

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE The most frequently mutated oncogene in cancer is KRAS, which uses alternative fourth exons to generate two gene products (KRAS4A and KRAS4B) that differ only in their C-terminal membrane-targeting region<sup>1</sup>. 31827279

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Despite its direct involvement in malignancy and intensive effort, direct inhibition of KRAS via pharmacological inhibitors has been challenging. 31289919

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles. 31413817

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE There appear to be no studies analyzing biomarkers of trace elements and KRAS mutations in any human cancer. 31066938

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE These results contribute to a better understanding of how the KRAS-membrane interaction is tuned by multiple factors whose identification could inform drug discovery efforts to disrupt this critical interaction in diseases such as cancer. 30559287

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE The proto-oncogene KRAS belongs among the most frequently mutated genes in all types of cancer and is also very important oncogene related to colorectal tumors. 30661213

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Antagonism between SNORD50A/B RNAs and specific SNARE proteins thus controls KRAS localization, signaling, and tumorigenesis, and disrupting SNARE-enabled KRAS function represents a potential therapeutic opportunity in KRAS-driven cancer. 31712554

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE TEAD deregulation affects well-established cancer genes such as KRAS, BRAF, LKB1, NF2, and MYC, and its transcriptional output plays an important role in tumor progression, metastasis, cancer metabolism, immunity, and drug resistance. 31212916

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE In normal cells, KRAS-activity is tightly controlled, but with specific mutations, the KRAS protein is persistently activated, giving cells a growth advantage resulting in cancer. 31399087

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Dual Targeting of Autophagy and MEK in KRAS Mutant Cancer. 31208693

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE In-silico Design of Peptide Inhibitors of K-Ras Target in Cancer Disease. 31838977

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Targeting the untargetable KRAS in cancer therapy. 31649840

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE The comparison of KRAS mutation status between EBC-DNA and cancer tissue was performed in 19 cases. 30368666

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Efforts to discover new approaches targeting this menacing culprit have been ongoing for years without much success, and with incidences of KRAS positive cancer patients being on the rise, researchers are now turning towards immunotherapies as the way forward. 31483231

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE K-RAS mutation-positive FN/SFN nodules have a 50% risk of malignancy and surgery should be recommended. 31295281

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE We first demonstrate our droplet digital PCR assay can robustly detect common cancer mutants including KRAS G12D spiked in wild-type genomic background or isolated from patient samples with 100% specificity. 30735225

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Our findings support the hypothesis that the KRAS-variant has a fundamental biological impact on normal cellular biology, that is conserved in these patients when they develop cancer. 30932013

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Drug resistance and tumor heterogeneity are formidable challenges in cancer medicine, which is particularly relevant for KRAS-mutant cancers, the epitome of malignant tumors recalcitrant to targeted therapy efforts and first-line chemotherapy. 31431614

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Pancreatic ductal adenocarcinoma (PDAC) is a dominantly (~95%) KRAS-mutant cancer that has extremely poor prognosis, in part this is due to its strong intrinsic resistance towards almost all therapeutic agents. 30653981

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Epithelial cells in both ovarian endometriotic tissue and the normal endometrium harbor somatic mutations in cancer-associated genes such as phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and KRAS proto-oncogene, GTPase (KRAS). 31621846

2019